{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:42:35Z","timestamp":1792636955393,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","award":["R016733022"],"award-info":[{"award-number":["R016733022"]}],"id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","award":["R016837001"],"award-info":[{"award-number":["R016837001"]}],"id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010731","name":"Chiang Mai University Faculty of Medicine","doi-asserted-by":"publisher","award":["159\\u201368"],"award-info":[{"award-number":["159\\u201368"]}],"id":[{"id":"10.13039\/501100010731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A660313"],"award-info":[{"award-number":["N42A660313"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119609","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:30:37Z","timestamp":1780939837000},"page":"119609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME)"],"prefix":"10.1016","volume":"200","author":[{"given":"Saitong","family":"Muneekaew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3634-1881","authenticated-orcid":false,"given":"Aussara","family":"Panya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1000-8636","authenticated-orcid":false,"given":"Kritayaporn","family":"Saiprayong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koollawat","family":"Chupradit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thunchanok","family":"Nuchphongsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasut","family":"Sasithong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3169-5509","authenticated-orcid":false,"given":"Somsakul Pop","family":"Wongpalee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natthanich","family":"Boonsatit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2508-5760","authenticated-orcid":false,"given":"Methichit","family":"Wattanapanitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119609_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103835","article-title":"Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050","volume":"79","author":"Fu","year":"2025","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib2","doi-asserted-by":"crossref","first-page":"9347","DOI":"10.1038\/s41598-025-93883-9","article-title":"The global burden of breast cancer among women of reproductive age: a comprehensive analysis","volume":"15","author":"Cai","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib3","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer Journal Clinicians"},{"key":"10.1016\/j.biopha.2026.119609_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119609_bib6","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-CT069","article-title":"Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)","volume":"77","author":"Cort\u00e9s","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41523-024-00679-7","article-title":"Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC","volume":"10","author":"Im","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119609_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"New. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119609_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"New. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119609_bib10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/14712598.2022.2098675","article-title":"Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer","volume":"22","author":"Sewnath","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100046","article-title":"Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy","volume":"6","author":"Fuc\u00e0","year":"2021","journal-title":"ESMO Open."},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4049\/jimmunol.118.1.187","article-title":"MJC: Monocyte function in Man","volume":"118","author":"Territo","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119609_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fimmu.2017.00280","article-title":"Fc\u03b3 Receptor Heterogeneity in Leukocyte Functional Responses","volume":"8","author":"Rosales","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119609_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00262-024-03856-6","article-title":"Targeting immune checkpoints on myeloid cells: current status and future directions","volume":"74","author":"Ma","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.biopha.2026.119609_bib15","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3390\/biology10111178","article-title":"Siglecs as Therapeutic Targets in Cancer","volume":"10","author":"Lim","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.biopha.2026.119609_bib16","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1111\/febs.70192","article-title":"Enhancing macrophage phagocytosis of cancers by disrupting the SIRP\u03b1\/CD47 signaling axis and targeting MUC1 antigen","volume":"292","author":"Muneekaew","year":"2025","journal-title":"FEBS J,"},{"issue":"2","key":"10.1016\/j.biopha.2026.119609_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13361","article-title":"Lack of SIRP-alpha reduces lung cancer growth in mice by promoting anti-tumour ability of macrophages and neutrophils","volume":"56","author":"Pan","year":"2023","journal-title":"Cell. Prolif."},{"issue":"5","key":"10.1016\/j.biopha.2026.119609_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051260","article-title":"Siglec Ligands","volume":"10","author":"Gonzalez-Gil","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119609_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104354","article-title":"Inhibitory Siglec-sialic acid interactions in balancing immunological activation and tolerance during viral infections","volume":"86","author":"Saini","year":"2022","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.biopha.2026.119609_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/sji.12455","article-title":"Siglec-7 defines a highly functional natural killer cell subset and inhibits cell-mediated activities","volume":"84","author":"Shao","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.biopha.2026.119609_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-4598-9-11","article-title":"aMSP: MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells","volume":"9","author":"Gubbels","year":"2010","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib22","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41467-021-21550-4","article-title":"Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2026.119609_bib23","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbrc.2008.02.111","article-title":"Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs","volume":"369","author":"Ando","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2026.119609_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiaf018","article-title":"Development of 2LTRZFP-expressing induced pluripotent stem cells as a potential anti-HIV-1 gene therapy against viral integration","volume":"117","author":"Saiprayong","year":"2025","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/s13287-024-04029-z","article-title":"Phenotypic and transcriptomic profiling of induced pluripotent stem cell (iPSC)-derived NK cells and their cytotoxicity against cancers","volume":"15","author":"Thongsin","year":"2024","journal-title":"Stem Cell. Res. & Ther."},{"key":"10.1016\/j.biopha.2026.119609_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.scr.2018.01.013","article-title":"Generation of a human induced pluripotent stem cell line (MUSIi001-A) from caesarean section scar fibroblasts using Sendai viral vectors","volume":"27","author":"Wattanapanitch","year":"2018","journal-title":"Stem Cell. Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119609_bib27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00262-024-03759-6","article-title":"Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers","volume":"73","author":"Chupradit","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.biopha.2026.119609_bib28","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s10637-025-01568-x","article-title":"Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer","volume":"43","author":"Chiawpanit","year":"2025","journal-title":"Investig. New. Drugs"},{"issue":"8","key":"10.1016\/j.biopha.2026.119609_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071098","article-title":"Efficient, Long Term Production of Monocyte-Derived Macrophages from Human Pluripotent Stem Cells under Partly-Defined and Fully-Defined Conditions","volume":"8","author":"Wilgenburg","year":"2013","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102827","article-title":"Differentiation of monocytes and polarized M1\/M2 macrophages from human induced pluripotent stem cells","volume":"5","author":"Park","year":"2024","journal-title":"STAR Protoc."},{"issue":"2","key":"10.1016\/j.biopha.2026.119609_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2026.104590","article-title":"Protocol for assessing anti-Siglec-9 antibody-mediated tumor phagocytosis by macrophages using pH-sensitive dyes and flow cytometry","volume":"7","author":"Muneekaew","year":"2026","journal-title":"STAR Protoc."},{"issue":"14","key":"10.1016\/j.biopha.2026.119609_bib32","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119609_bib33","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2567.2008.02878.x","article-title":"Interleukin-15 stimulates macrophages to activate CD4+ T cells: a role in the pathogenesis of rheumatoid arthritis?","volume":"126","author":"R\u00fcckert","year":"2009","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.biopha.2026.119609_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.immuni.2012.05.029","article-title":"Inflammatory Monocytes Activate Memory CD8+ T and Innate NK Lymphocytes Independent of Cognate Antigen during Microbial Pathogen Invasion","volume":"37","author":"Soudja","year":"2012","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.biopha.2026.119609_bib36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"52","key":"10.1016\/j.biopha.2026.119609_bib37","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.13411","article-title":"An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.biopha.2026.119609_bib38","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/sj.cdd.4400575","article-title":"Interleukin-15 is a potent survival factor in the prevention of spontaneous but not CD95-induced apoptosis in CD4 and CD8 T lymphocytes of HIV-infected individuals. Correlation with its ability to increase BCL-2 expression","volume":"6","author":"Naora","year":"1999","journal-title":"Cell. Death & Differ."},{"issue":"28","key":"10.1016\/j.biopha.2026.119609_bib39","doi-asserted-by":"crossref","first-page":"26107","DOI":"10.1074\/jbc.M011475200","article-title":"Interleukin-15 Prevents Mouse Mast Cell Apoptosis through STAT6-mediated Bcl-xL Expression","volume":"276","author":"Masuda","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119609_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2024.101887","article-title":"Siglecs as modulators of macrophage phenotype and function","volume":"73","author":"Kukan","year":"2024","journal-title":"Semin. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119609_bib41","article-title":"Proximity Labeling and Genetic Screening Reveal that DSG2 is a Counter Receptor of Siglec-9 and Suppresses Macrophage Phagocytosis","volume":"12","author":"Wu","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"3","key":"10.1016\/j.biopha.2026.119609_bib42","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.apsb.2024.10.014","article-title":"Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment","volume":"15","author":"Naatz","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"7769","key":"10.1016\/j.biopha.2026.119609_bib43","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119609_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118161","article-title":"Enhancing T cell cytotoxicity against lung cancer with an \u03b1PD-L1 protein engager and gemcitabine combination therapy","volume":"188","author":"Thepmalee","year":"2025","journal-title":"Biomed. & Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib45","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41598-022-09964-6","article-title":"Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells","volume":"12","author":"Wathikthinnakon","year":"2022","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2026.119609_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/imt-2023-0256","article-title":"A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3\/CD28 Co-Engagement","volume":"16","author":"Chen","year":"2024","journal-title":"Immunotherapy"},{"issue":"41","key":"10.1016\/j.biopha.2026.119609_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202309697","article-title":"Targeting Dual Immune Checkpoints PD-L1 and HLA-G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer","volume":"11","author":"Lin","year":"2024","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41420-025-02329-8","article-title":"Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics","volume":"11","author":"Passariello","year":"2025","journal-title":"Cell. Death Discov."},{"issue":"29","key":"10.1016\/j.biopha.2026.119609_bib49","doi-asserted-by":"crossref","first-page":"11272","DOI":"10.1039\/D4SC00851K","article-title":"Macrophage-engaging peptidic bispecific antibodies (pBsAbs) for immunotherapy via a facile bioconjugation strategy","volume":"15","author":"Shao","year":"2024","journal-title":"Chem. Sci."},{"issue":"6_ement","key":"10.1016\/j.biopha.2026.119609_bib50","article-title":"Abstract 183: A novel bispecific antibody macrophage engager (BiME) designed for the treatment of solid tumors","volume":"84","author":"Sun","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119609_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151761","article-title":"Targeting ALPPL2 with a novel CD89 bispecific antibody reprograms macrophages to enhance anti-tumor immunity","volume":"762","author":"Xu","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0022-1759(00)00347-1","article-title":"Bispecific antibody-mediated destruction of Hodgkin\u2019s lymphoma cells","volume":"248","author":"Sundarapandiyan","year":"2001","journal-title":"J. Immunol. Methods"},{"issue":"13_ement","key":"10.1016\/j.biopha.2026.119609_bib53","article-title":"Abstract 559: Preclinical characterization of the bispecific EGFR\/CD16A innate immune cell engager AFM24 for the treatment of EGFR-expressing solid tumors","volume":"79","author":"Kluge","year":"2019","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2026.119609_bib54","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-24-1991","article-title":"First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors","volume":"31","author":"El-Khoueiry","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119609_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008295","article-title":"Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice","volume":"12","author":"Khoshtinat Nikkhoi","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-79156-7","article-title":"Syk facilitates phagosome-lysosome fusion by regulating actin-remodeling in complement-mediated phagocytosis","volume":"10","author":"Tabata","year":"2020","journal-title":"Sci. Rep."},{"issue":"22","key":"10.1016\/j.biopha.2026.119609_bib57","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1007\/s00216-016-9585-x","article-title":"VHH antibodies: emerging reagents for the analysis of environmental chemicals","volume":"408","author":"Bever","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2026.119609_bib58","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4049\/jimmunol.0902307","article-title":"IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis","volume":"184","author":"Inoue","year":"2010","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119609_bib59","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.trecan.2023.11.009","article-title":"Targeting myeloid cells for cancer immunotherapy: Siglec-7\/9\/10\/15 and their ligands","volume":"10","author":"Boelaars","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.biopha.2026.119609_bib60","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fimmu.2023.1178817","article-title":"Disruption of the sialic acid\/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells","volume":"14","author":"Lustig","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib61","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbrc.2014.06.009","article-title":"A soluble form of Siglec-9 provides an antitumor benefit against mammary tumor cells expressing MUC1 in transgenic mice","volume":"450","author":"Tomioka","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2026.119609_bib62","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2024.01.028","article-title":"Increased Siglec-9\/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy","volume":"80","author":"Xiao","year":"2024","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119609_bib63","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2967\/jnumed.120.250696","article-title":"First-in-Humans Study of (68)Ga-DOTA-Siglec-9, a PET Ligand Targeting Vascular Adhesion Protein 1","volume":"62","author":"Viitanen","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119609_bib64","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119609_bib65","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"issue":"5","key":"10.1016\/j.biopha.2026.119609_bib66","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.237800","article-title":"Macrophages show higher levels of engulfment after disruption of cis interactions between CD47 and the checkpoint receptor SIRP\u03b1","volume":"133","author":"Hayes","year":"2020","journal-title":"J. Cell. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119609_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060565","article-title":"Efficient genetic safety switches for future application of iPSC-derived cell transplants","volume":"11","author":"Dahlke","year":"2021","journal-title":"J. Pers. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119609_bib68","doi-asserted-by":"crossref","DOI":"10.1155\/jimr\/9994439","article-title":"Progression in the in vitro macrophage expansion","volume":"2025","author":"Wei","year":"2025","journal-title":"J. Immunol. Res."},{"issue":"5954","key":"10.1016\/j.biopha.2026.119609_bib69","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1126\/science.1176056","article-title":"MafB\/c-Maf deficiency enables self-renewal of differentiated functional macrophages","volume":"326","author":"Aziz","year":"2009","journal-title":"Science"}],"updated-by":[{"DOI":"10.1016\/j.biopha.2026.119725","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000}},{"DOI":"10.1016\/j.biopha.2026.119725","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:59:47Z","timestamp":1787439587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226006451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":69,"alternative-id":["S0753332226006451"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119609","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME)","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119609"}}